Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
January 12, 2026 updated by: University of Washington
SPECTRA: Supraphysiological Androgen to Enhance Treatment Activity
This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer).
In patients that have developed progressive cancer in spite of standard hormonal treatment, administering supraphysiological testosterone may result in regression of tumors by causing deoxyribonucleic acid (DNA) damage in tumor cells that have adapted to low testosterone conditions.
Carboplatin is in a class of medications known as platinum-containing compounds.
Carboplatin works by killing, stopping or slowing the growth of tumor cells.
Etoposide is in a class of medications known as podophyllotoxin derivatives.
It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells.
Radioactive drugs, such as LuPSMA, may carry radiation directly to tumor cells and not harm normal cells.
Giving supraphysiological levels of testosterone and carboplatin or etoposide or LuPSMA together may be an effective treatment for metastatic castration-resistant prostate cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
- Drug: Carboplatin
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Procedure: Computed Tomography
- Procedure: Biospecimen Collection
- Procedure: Single Photon Emission Computed Tomography
- Procedure: Bone Scan
- Drug: Testosterone Cypionate
- Drug: Etoposide
- Procedure: Biopsy Procedure
- Procedure: Dual X-ray Absorptiometry
- Other: Radioconjugate
- Other: Gallium Ga 68-PSMA-617
- Procedure: Positron Emission Tomography
Detailed Description
OUTLINE:
Patients are assigned based on personal preference to 1 of 3 cohorts.
COHORT I: Patients are then assigned to 1 of 3 sub-cohorts within cohort I.
COHORT Ia: Patients continue to receive ADT and receive testosterone cypionate intramuscularly (IM) on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin intravenously (IV) on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT Ib: Patients continue to receive ADT and receive carboplatin IV on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT Ic: Patients continue to receive ADT and receive testosterone cypionate IM and carboplatin IV on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT II: Patients are then assigned to 1 of 3 sub-cohorts within cohort II.
COHORT IIa: Patients continue to receive ADT and receive testosterone cypionate IM on day 1 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide orally (PO) once daily (QD) on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT IIb: Patients continue to receive ADT and receive etoposide PO QD on days 1-14 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT IIc: Patients continue to receive ADT and receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
COHORT III: Patients are assigned to 1 of 3 sub-cohorts within cohort III.
COHORT IIIa: Patients continue to receive ADT and receive testosterone cypionate intramuscularly (IM) on day 1 of cycles 1-6. Patients receive LuPSMA IV on day 1 of cycles 2-6. Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive testosterone cypionate intramuscularly (IM) on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo 68Ga-PSMA positron emission tomography (PET) at screening and single photon emission computed tomography (SPECT)/CT throughout the study.
COHORT IIIb: Patients continue to receive ADT and LuPSMA IV on day 1 of cycles 1-6. Patients also receive receive testosterone cypionate IM on day 1 of cycles 2-6 . Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive testosterone cypionate IM on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo 68Ga-PSMA PET at screening and single SPECT/CT throughout the study.
COHORT IIIc: Patients continue to receive ADT and receive testosterone cypionate IM on day 1 and LuPSMA IV on day 1 of cycles 1-6. Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive testosterone cypionate IM on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo 68Ga-PSMA PET at screening and single SPECT/CT throughout the study.
All patients undergo a biopsy on study and blood sample collection on study, and bone scans, dual x-ray absorptiometry (DEXA) and computed tomography (CT) scans throughout the trial. Patients may also undergo an optional second biopsy at the end of study treatment.
After completion of study treatment, patients are followed up at 30 days, and then every 6 months for 2 years.
Study Type
Interventional
Enrollment (Estimated)
69
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Schweizer
- Phone Number: 206-606-6252
- Email: schweize@uw.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutch/University of Washington Cancer Consortium
-
Principal Investigator:
- Michael Schweizer
-
Contact:
- Michael Schweizer
- Phone Number: 206-606-6252
- Email: schweize@uw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Must be willing to provide informed consent prior to any study specific procedures
- Age >= 18 years
- Documented histologically confirmed adenocarcinoma of the prostate
- Patient must have evidence of castration resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate serum testosterone level (i.e., =< 50 mg/dL)
- PSA must be at least 2 ng/ml and rising on two successive measurements at least two weeks apart
- Patients must have progressed on at least one prior next-generation androgen receptor-signalling inhibitor (e.g., abiraterone, enzalutamide, etc.). There must be at least a 2-week washout period after stopping the most recent approved therapy for metastatic castration-resistant prostate cancer (mCRPC) (e.g., abiraterone, enzalutamide, Ra-223, sipuleucel-t) prior to cycle 1, day 1. If applicable, patients should be weaned off steroids at least 1 week prior to starting treatment
- Subjects enrolling to Cohort 3 must demonstrate evidence of PSMA expression on 68Ga-PSMA-11 PET as defined in the VISION trial
- No prior chemotherapy for the treatment of mCRPC. Patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer
- Prior treatment with non-chemotherapy investigational agents is permitted. There must be at least a 2-week washout period after stopping any investigational cancer agent prior to cycle 1, day 1
- Hemoglobin >= 9 g/dL with no blood transfusion in the past 28 days (within 30 days prior to administration of study treatment)
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 30 days prior to administration of study treatment)
- Platelet count >= 100 x 10^9/L (within 30 days prior to administration of study treatment)
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 30 days prior to administration of study treatment)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be =< 5x ULN (within 30 days prior to administration of study treatment)
- Patients must have creatinine clearance estimated using the Cockcroft-Gault equation or based on 24 hour urine test of >= 51 mL/min (within 30 days prior to administration of study treatment)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Patients must have a life expectancy >= 16 weeks
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
- At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT, positron emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment
- Must be willing to undergo metastatic biopsy and have a lesion amenable for biopsy
- Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 6 months after last dose of study drug(s) to prevent pregnancy in a partner
Exclusion Criteria:
- Involvement in the planning and/or conduct of the study
- Other malignancy unless curatively treated with no evidence of disease for >= 2 years except: adequately treated non-melanoma skin cancer, non-muscle invasive bladder cancer
- Persistent toxicities (Common Terminology Criteria for Adverse Event (CTCAE) grade > 2) caused by previous cancer therapy, excluding alopecia
- Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
- Use of corticosteroids at a dose equivalent to > 10 mg of prednisone daily
- Planning to receive concurrent treatment with another systemic cancer therapy, aside from a luteinizing hormone releasing hormone (LHRH) analogue
- Use of warfarin is not permitted. Low-molecular weight heparin and direct oral anticoagulants are allowed, but their use should be discussed with the principal investigator (PI) first
- Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
- Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, uncontrolled hypertension (blood pressure [BP] >= 165/100), history of prior stroke, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease or any psychiatric disorder that prohibits obtaining informed consent
- Patients with a known hypersensitivity to the testosterone cypionate, etoposide, carboplatin or any of the excipients of these products
- Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
- Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study
- Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule
- Evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction)
Patients with pain attributable to their prostate cancer.
- Excluded due to concern for pain flare due to testosterone supplementation
- Tumor causing urinary outlet obstruction that requires catheterization for voiding. Patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll. Patients with percutaneous nephrostomy tubes will also be permitted to enroll
Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulation.
- Excluded due to risk of venous thromboembolism from hormone supplementation
Patients with NYHA (New York Heart Association) class III or IV heart failure or history of a prior myocardial infarction (MI) within 5 years of enrollment to the study.
- Excluded due to increased risk of cardiovascular events with testosterone supplementation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Cohort Ia (testosterone cypionate, carboplatin)
Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycle 1.
Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
|
|
Active Comparator: Cohort Ib (testosterone cypionate, carboplatin)
Patients continue to receive ADT per standard of care and receive carboplatin IV on day 1 of cycle 1.
Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
|
|
Experimental: Cohort Ic (testosterone cypionate, carboplatin)
Patients continue to receive ADT per standard of care and receive testosterone cypionate IM and carboplatin IV on day 1 of cycle 1.
Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
|
Given IV
Other Names:
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
|
|
Active Comparator: Cohort IIa (testosterone cypionate, etoposide)
Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycle 1.
Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Given PO
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
|
|
Active Comparator: Cohort IIb (testosterone cypionate, etoposide)
Patients continue to receive ADT per standard of care and receive etoposide PO QD on days 1-14 of cycle 1.
Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Given PO
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
|
|
Experimental: Cohort IIc (testosterone cypionate, etoposide)
Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of cycle 1.
Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Given PO
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
|
|
Experimental: Cohort IIIa (ADT, testosterone cypionate, LuPSMA)
Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycles 1-6.
Patients receive LuPSMA IV on day 1 of cycles 2-6.
Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients then receive testosterone cypionate IM on day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo a biopsy on study and blood sample collection on study, and bone scans, DEXA and CT scans throughout the trial.
Patients may also undergo an optional second biopsy at the end of study treatment.
Patients also undergo 68Ga-PSMA PET at screening and SPECT/CT throughout the study.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo SPECT/CT
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
Given LuPSMA IV
Other Names:
Given gallium 68Ga-PSMA-617
Other Names:
Undergo 68Ga-PSMA PET
Other Names:
|
|
Experimental: Cohort IIIb (ADT, testosterone cypionate, LuPSMA)
Patients continue to receive ADT per standard of care and LuPSMA IV on day 1 of cycles 1-6.
Patients also receive testosterone cypionate IM on day 1 of cycles 2-6 .
Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients receive testosterone cypionate IM on day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients also undergo 68Ga-PSMA PET at screening and SPECT/CT throughout the study.
All patients undergo a biopsy on study and blood sample collection on study, and bone scans, DEXA and CT scans throughout the trial.
Patients may also undergo an optional second biopsy at the end of study treatment.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo SPECT/CT
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
Given LuPSMA IV
Other Names:
Given gallium 68Ga-PSMA-617
Other Names:
Undergo 68Ga-PSMA PET
Other Names:
|
|
Experimental: Cohort IIIc (ADT, testosterone cypionate, LuPSMA)
Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 and LuPSMA IV on day 1 of cycles 1-6.
Cycles repeat every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients then receive testosterone cypionate IM on day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients also undergo 68Ga-PSMA PET at screening and SPECT/CT throughout the study.
All patients undergo a biopsy on study and blood sample collection on study, and bone scans, DEXA and CT scans throughout the trial.
Patients may also undergo an optional second biopsy at the end of study treatment.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Undergo SPECT/CT
Other Names:
Undergo bone scan
Other Names:
Given IM
Other Names:
Undergo a biopsy
Other Names:
Undergo DEXA
Other Names:
Given LuPSMA IV
Other Names:
Given gallium 68Ga-PSMA-617
Other Names:
Undergo 68Ga-PSMA PET
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Greater than or equal to 50% decline in prostate-specific antigen from baseline (PSA50) response rate
Time Frame: From baseline up to 3 years
|
Will assess >= 50% decline in PSA following treatment with combination bipolar androgen therapy (BAT) and genotoxic chemotherapy (at least 12 weeks of total therapy).
Will be calculated as the percentage with 95% confidence interval (CI) of the total number of subjects that achieved a PSA50 response.
|
From baseline up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiographic response
Time Frame: Up to 3 years
|
Will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Best radiographic response for each patient will be presented in a waterfall plot.
|
Up to 3 years
|
|
Radiographic progression-free survival (PFS)
Time Frame: The start of treatment until disease progression (per modified RECIST criteria or PCWG3 criteria for bone lesions), clinical progression (as determined by the treating physician), or death, whichever occurs first, assessed up to 3 years
|
Will be assessed using RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3) criteria.
Will be presented with Kaplan-Meier curves, and the median survival with 95% CI will be calculated.
Rates will be reported as percentages with 95% CI.
|
The start of treatment until disease progression (per modified RECIST criteria or PCWG3 criteria for bone lesions), clinical progression (as determined by the treating physician), or death, whichever occurs first, assessed up to 3 years
|
|
PSA PFS
Time Frame: Time from the start of treatment until PSA progression (as defined by PCWG3 criteria), assessed up to 3 years
|
Will be assessed using PCWG3 criteria.
Will be presented with Kaplan-Meier curves, and the median survival with 95% CI will be calculated.
Rates will be reported as percentages with 95% CI.
Best on study PSA for each patient will be presented in a waterfall plot.
|
Time from the start of treatment until PSA progression (as defined by PCWG3 criteria), assessed up to 3 years
|
|
Overall survival
Time Frame: The start of treatment until death from any cause, assessed up to 3 years
|
Will be presented with Kaplan-Meier curves, and the median survival with 95% CI will be calculated.
Rates will be reported as percentages with 95% CI.
|
The start of treatment until death from any cause, assessed up to 3 years
|
|
Incidence of adverse events
Time Frame: Up to 30 days after completion of study treatment
|
Will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
Up to 30 days after completion of study treatment
|
|
Patient-reported outcome measure (PROMS) questionnaires
Time Frame: Up to 3 years
|
Will be assessed by average change in quality of life (QOL) scores (total and for each domain) for each survey will be calculated at each timepoint.
A paired t-test will used to assess for statistically significant changes in QOL from baseline to subsequent timepoints, and linear mixed effects models will be used to evaluate trends over all timepoints.
|
Up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Schweizer, Fred Hutch/University of Washington Cancer Consortium
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 21, 2024
Primary Completion (Estimated)
March 31, 2027
Study Completion (Estimated)
December 31, 2027
Study Registration Dates
First Submitted
August 21, 2023
First Submitted That Met QC Criteria
September 8, 2023
First Posted (Actual)
September 15, 2023
Study Record Updates
Last Update Posted (Estimated)
January 14, 2026
Last Update Submitted That Met QC Criteria
January 12, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Prostatic Neoplasms
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Organic Chemicals
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Surgical Procedures, Operative
- Cytological Techniques
- Cytodiagnosis
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carbohydrates
- Physical Phenomena
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glucosides
- Glycosides
- Coordination Complexes
- Steroids
- Fused-Ring Compounds
- Diagnostic Techniques, Surgical
- Diagnostic Imaging
- Chemistry Techniques, Analytical
- Spectrum Analysis
- Gonadal Steroid Hormones
- Gonadal Hormones
- Electromagnetic Phenomena
- Magnetic Phenomena
- Androstenes
- Androstanes
- Electromagnetic Radiation
- Radiation
- Radiation, Ionizing
- Androstenols
- Testosterone Congeners
- Radiography
- Densitometry
- Photometry
- Testosterone
- Etoposide
- Carboplatin
- Methyltestosterone
- testosterone 17 beta-cypionate
- Biopsy
- Specimen Handling
- Magnetic Resonance Spectroscopy
- X-Rays
- Absorptiometry, Photon
- Testosterone Propionate
Other Study ID Numbers
- RG1123642
- NCI-2023-05597 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 2P50CA097186 (U.S. NIH Grant/Contract)
- FHIRB0020106 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Castration-Resistant Prostate Carcinoma
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationRecruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Radiopharm Theranostics, LtdRecruitingCastration-resistant Prostate CancerAustralia
-
Barts & The London NHS TrustCompletedCastration Resistant Prostate CancerUnited Kingdom
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Not yet recruitingCastration-resistant Prostate CancerChina
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Pedro Barata, MD, MScNot yet recruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Hoffmann-La RocheRecruitingMetastatic Castration-Resistant Prostate CancerAustralia, Canada, Spain, France, United States, South Korea, Brazil, Turkey (Türkiye), Italy, United Kingdom
-
R-Pharm International, LLCActive, not recruitingMetastatic Castration-resistant Prostate CancerRussia
-
University of Wisconsin, MadisonGE HealthcareNot yet recruitingMetastatic Castration-resistant Prostate CancerUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting
-
Zhejiang Cancer HospitalRecruiting
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
Sun Yat-sen UniversityNot yet recruiting
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
Tang-Du HospitalRecruitingHead & Neck CancerChina
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland